Literature DB >> 22313720

Lifespan persistence of ADHD: the life transition model and its application.

Atilla Turgay1, David W Goodman, Philip Asherson, Robert A Lasser, Thomas F Babcock, Michael L Pucci, Russell Barkley.   

Abstract

BACKGROUND: The understanding that attention-deficit/hyperactivity disorder (ADHD) often persists throughout life has heightened interest of patients, families, advocates, and professionals in a longitudinal approach to management. Such an approach must recognize and address known patient- and systems-based challenges of long-term mental health treatment, shifting of clinical presentations of ADHD, and commonality of psychiatric comorbidity with ADHD.
OBJECTIVE: The ADHD Life Transition Model is a step toward developing criteria to optimize recognition and clinical management of ADHD (eg, response, remission) across an individual's lifespan and across diverse medical subspecialties. To support therapeutic efficiency and adaptability, our proposed model highlights periods when external resources for managing ADHD are reduced, cognitive and behavioral stressors are increased, and individuals may be reevaluating how they perceive, accept, and adhere to ADHD treatment. Such a model aims to support the clinical community by placing in context new findings, which suggest that the prevention of adult psychopathology in individuals with pediatric ADHD may be possible.
CONCLUSIONS: The ADHD Life Transition Model seeks to improve care for individuals with ADHD by (1) underscoring that ADHD persists beyond childhood in at least two-thirds of patients, (2) raising awareness of the need to approach ADHD from a chronic illness standpoint, and (3) increasing mental health professionals' diligence in symptom recognition and management of ADHD across developmental phases from childhood through adulthood. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22313720     DOI: 10.4088/JCP.10m06628

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  35 in total

1.  Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers.

Authors:  Sharlene Kaye; Josep Antoni Ramos-Quiroga; Geurt van de Glind; Frances R Levin; Stephen V Faraone; Steve Allsop; Louisa Degenhardt; Franz Moggi; Csaba Barta; Maija Konstenius; Johan Franck; Arvid Skutle; Eli-Torild Bu; Maarten W J Koeter; Zsolt Demetrovics; Máté Kapitány-Fövény; Robert A Schoevers; Katelijne van Emmerik-van Oortmerssen; Pieter-Jan Carpentier; Geert Dom; Sofie Verspreet; Cleo L Crunelle; Jesse T Young; Susan Carruthers; Joanne Cassar; Melina Fatséas; Marc Auriacombe; Brian Johnson; Matthew Dunn; Ortal Slobodin; Wim van den Brink
Journal:  J Atten Disord       Date:  2016-02-27       Impact factor: 3.256

2.  Organisation of services for managing ADHD.

Authors:  D R Coghill
Journal:  Epidemiol Psychiatr Sci       Date:  2016-12-22       Impact factor: 6.892

3.  Deficits in inhibitory force control in young adults with ADHD.

Authors:  Kristina A Neely; Peiyuan Wang; Amanda P Chennavasin; Shaadee Samimy; Jacqueline Tucker; Andrea Merida; Koraly Perez-Edgar; Cynthia Huang-Pollock
Journal:  Neuropsychologia       Date:  2017-03-09       Impact factor: 3.139

Review 4.  Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.

Authors:  Jose Martinez-Raga; Amparo Ferreros; Carlos Knecht; Raquel de Alvaro; Eloisa Carabal
Journal:  Ther Adv Drug Saf       Date:  2016-11-29

5.  Trajectories of ADHD severity over 10 years from childhood into adulthood.

Authors:  Mini Tandon; Rebecca Tillman; Arpana Agrawal; Joan Luby
Journal:  Atten Defic Hyperact Disord       Date:  2016-02-01

6.  Gestational and peripubertal phthalate exposure in relation to attention performance in childhood and adolescence.

Authors:  Deborah J Watkins; John D Meeker; Marcela Tamayo-Ortiz; Brisa N Sánchez; Lourdes Schnaas; Karen E Peterson; Martha María Téllez-Rojo
Journal:  Environ Res       Date:  2021-02-25       Impact factor: 6.498

7.  Update on optimal use of lisdexamfetamine in the treatment of ADHD.

Authors:  Vishal Madaan; Venkata Kolli; Durga P Bestha; Manan J Shah
Journal:  Neuropsychiatr Dis Treat       Date:  2013-07-22       Impact factor: 2.570

8.  Chronic Care for Attention-Deficit/Hyperactivity Disorder: Clinical Management from Childhood Through Adolescence.

Authors:  Cierra M Moss; Kristina B Metzger; Meghan E Carey; Nathan J Blum; Allison E Curry; Thomas J Power
Journal:  J Dev Behav Pediatr       Date:  2020 Feb/Mar       Impact factor: 2.988

9.  Adult-Onset ADHD: A Critical Analysis and Alternative Explanations.

Authors:  Lea E Taylor; Elizabeth A Kaplan-Kahn; Rachel A Lighthall; Kevin M Antshel
Journal:  Child Psychiatry Hum Dev       Date:  2021-03-18

10.  Sustained treatment effect in attention-deficit/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies.

Authors:  David W Goodman
Journal:  Ther Clin Risk Manag       Date:  2013-03-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.